{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000072","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.966864+00:00","generated_at":"2026-05-21T16:00:42.861749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025","bullets":["Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.","R&D expense $7.8M, G&A $3.0M; cash and equivalents $18.4M at March 31, 2025.","DFS event-driven interim analysis of Phase 2 AMPLIFY-7P trial (ELI-002 in PDAC) expected in Q3 2025.","FDA alignment on key design elements of planned Phase 3 study for ELI-002 in resected mKRAS PDAC.","Appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000072","json":"https://secwatch.observer/filing/0001601485-25-000072.json","markdown":"https://secwatch.observer/filing/0001601485-25-000072.md","text":"https://secwatch.observer/filing/0001601485-25-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/0001601485-25-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/angn-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:00:42.861749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}